AU2009294871A1 - Peptidomimetic macrocycles - Google Patents

Info

Publication number

AU2009294871A1

AU2009294871A1 AU2009294871A AU2009294871A AU2009294871A1 AU 2009294871 A1 AU2009294871 A1 AU 2009294871A1 AU 2009294871 A AU2009294871 A AU 2009294871A AU 2009294871 A AU2009294871 A AU 2009294871A AU 2009294871 A1 AU2009294871 A1 AU 2009294871A1

Authority

AU

Australia

Prior art keywords

amino acid

peptidomimetic macrocycle

peptidomimetic

macrocycle

alkyl

Prior art date

2008-09-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000816 peptidomimetic Substances 0.000 title claims description 239
• 150000002678 macrocyclic compounds Chemical class 0.000 title claims description 233
• 150000001413 amino acids Chemical class 0.000 claims description 171
• 125000000217 alkyl group Chemical group 0.000 claims description 73
• 125000005647 linker group Chemical group 0.000 claims description 71
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
• 238000000034 method Methods 0.000 claims description 49
• 125000000304 alkynyl group Chemical group 0.000 claims description 46
• 125000003342 alkenyl group Chemical group 0.000 claims description 45
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 45
• 108090000623 proteins and genes Proteins 0.000 claims description 43
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 40
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 40
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
• 125000003118 aryl group Chemical group 0.000 claims description 33
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 32
• 102000004169 proteins and genes Human genes 0.000 claims description 32
• 206010028980 Neoplasm Diseases 0.000 claims description 29
• 239000003814 drug Substances 0.000 claims description 21
• 125000002947 alkylene group Chemical group 0.000 claims description 19
• 230000003993 interaction Effects 0.000 claims description 19
• 229940124597 therapeutic agent Drugs 0.000 claims description 19
• 125000004450 alkenylene group Chemical group 0.000 claims description 18
• 125000004419 alkynylene group Chemical group 0.000 claims description 17
• 125000002993 cycloalkylene group Chemical group 0.000 claims description 17
• 125000004474 heteroalkylene group Chemical group 0.000 claims description 17
• 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 17
• 125000004122 cyclic group Chemical group 0.000 claims description 16
• 229910002091 carbon monoxide Inorganic materials 0.000 claims description 14
• 229910052736 halogen Inorganic materials 0.000 claims description 14
• 150000002367 halogens Chemical class 0.000 claims description 14
• 229910052739 hydrogen Inorganic materials 0.000 claims description 14
• 230000000694 effects Effects 0.000 claims description 13
• 239000001257 hydrogen Substances 0.000 claims description 13
• 201000011510 cancer Diseases 0.000 claims description 10
• 239000004971 Cross linker Substances 0.000 claims description 9
• 230000033115 angiogenesis Effects 0.000 claims description 8
• 125000000732 arylene group Chemical group 0.000 claims description 8
• 125000005549 heteroarylene group Chemical group 0.000 claims description 8
• 229910005965 SO 2 Inorganic materials 0.000 claims description 5
• 125000003277 amino group Chemical group 0.000 claims description 5
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
• 230000003042 antagnostic effect Effects 0.000 claims description 2
• 208000002780 macular degeneration Diseases 0.000 claims description 2
• 150000002431 hydrogen Chemical class 0.000 claims 2
• 125000001475 halogen functional group Chemical group 0.000 claims 1
• 229940024606 amino acid Drugs 0.000 description 172
• 235000001014 amino acid Nutrition 0.000 description 172
• 239000002243 precursor Substances 0.000 description 68
• 108090000765 processed proteins & peptides Proteins 0.000 description 68
• 150000001875 compounds Chemical class 0.000 description 50
• 102000004196 processed proteins & peptides Human genes 0.000 description 44
• -1 4-hydroxyphenylmethyl Chemical group 0.000 description 43
• 210000004027 cell Anatomy 0.000 description 40
• 239000003153 chemical reaction reagent Substances 0.000 description 39
• 125000004429 atom Chemical group 0.000 description 35
• 102100038885 Histone acetyltransferase p300 Human genes 0.000 description 33
• 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 description 33
• 101000978776 Mus musculus Neurogenic locus notch homolog protein 1 Proteins 0.000 description 33
• 230000015572 biosynthetic process Effects 0.000 description 31
• 235000018102 proteins Nutrition 0.000 description 29
• 230000027455 binding Effects 0.000 description 27
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 27
• 208000035475 disorder Diseases 0.000 description 26
• 229920001184 polypeptide Polymers 0.000 description 26
• 229910052799 carbon Inorganic materials 0.000 description 25
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 24
• 239000002253 acid Substances 0.000 description 24
• 238000003786 synthesis reaction Methods 0.000 description 24
• 201000010099 disease Diseases 0.000 description 23
• 238000005710 macrocyclization reaction Methods 0.000 description 23
• 239000000243 solution Substances 0.000 description 22
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
• 238000005804 alkylation reaction Methods 0.000 description 19
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 19
• 239000000203 mixture Substances 0.000 description 19
• 229910052717 sulfur Inorganic materials 0.000 description 18
• 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 description 16
• 206010021143 Hypoxia Diseases 0.000 description 16
• 125000000539 amino acid group Chemical group 0.000 description 16
• 238000003556 assay Methods 0.000 description 16
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 16
• 125000004432 carbon atom Chemical group C* 0.000 description 16
• 230000000875 corresponding effect Effects 0.000 description 16
• 229910052760 oxygen Inorganic materials 0.000 description 16
• 239000001301 oxygen Substances 0.000 description 16
• 239000007787 solid Substances 0.000 description 16
• 238000002360 preparation method Methods 0.000 description 15
• 239000007790 solid phase Substances 0.000 description 15
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
• 150000001345 alkine derivatives Chemical class 0.000 description 14
• 239000002904 solvent Substances 0.000 description 14
• 238000005755 formation reaction Methods 0.000 description 13
• 125000004435 hydrogen atom Chemical class [H]* 0.000 description 13
• 229920005989 resin Polymers 0.000 description 13
• 239000011347 resin Substances 0.000 description 13
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
• 238000006243 chemical reaction Methods 0.000 description 12
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 11
• 230000029936 alkylation Effects 0.000 description 11
• 230000001413 cellular effect Effects 0.000 description 11
• 125000005842 heteroatom Chemical group 0.000 description 11
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 11
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
• 230000006907 apoptotic process Effects 0.000 description 10
• 230000030833 cell death Effects 0.000 description 10
• 238000010647 peptide synthesis reaction Methods 0.000 description 10
• 125000001424 substituent group Chemical group 0.000 description 10
• 230000004083 survival effect Effects 0.000 description 10
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
• DGYHPLMPMRKMPD-UHFFFAOYSA-N L-propargyl glycine Natural products OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 9
• 238000002875 fluorescence polarization Methods 0.000 description 9
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
• 238000011282 treatment Methods 0.000 description 9
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 8
• 239000004472 Lysine Substances 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 235000004279 alanine Nutrition 0.000 description 8
• 239000007864 aqueous solution Substances 0.000 description 8
• IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 8
• 230000014509 gene expression Effects 0.000 description 8
• 230000007954 hypoxia Effects 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 229910052757 nitrogen Inorganic materials 0.000 description 8
• 230000002062 proliferating effect Effects 0.000 description 8
• 150000003839 salts Chemical class 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 238000006467 substitution reaction Methods 0.000 description 8
• XDTDZXZZJXVVOL-QMMMGPOBSA-N (2s)-2-amino-2-methylhept-6-ynoic acid Chemical compound OC(=O)[C@](N)(C)CCCC#C XDTDZXZZJXVVOL-QMMMGPOBSA-N 0.000 description 7
• FSBNDYYRTZBHAN-LURJTMIESA-N (2s)-2-amino-2-methylpent-4-ynoic acid Chemical compound OC(=O)[C@](N)(C)CC#C FSBNDYYRTZBHAN-LURJTMIESA-N 0.000 description 7
• 201000009030 Carcinoma Diseases 0.000 description 7
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
• 241000699670 Mus sp. Species 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• 239000003054 catalyst Substances 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 238000002474 experimental method Methods 0.000 description 7
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
• 239000012634 fragment Substances 0.000 description 7
• 125000006239 protecting group Chemical group 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 125000001431 2-aminoisobutyric acid group Chemical group [#6]C([#6])(N*)C(*)=O 0.000 description 6
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 6
• 108010049386 Aryl Hydrocarbon Receptor Nuclear Translocator Proteins 0.000 description 6
• 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 6
• DGYHPLMPMRKMPD-BYPYZUCNSA-N L-propargylglycine Chemical group OC(=O)[C@@H](N)CC#C DGYHPLMPMRKMPD-BYPYZUCNSA-N 0.000 description 6
• 102000040945 Transcription factor Human genes 0.000 description 6
• 108091023040 Transcription factor Proteins 0.000 description 6
• 239000000370 acceptor Substances 0.000 description 6
• 125000002619 bicyclic group Chemical group 0.000 description 6
• 235000018417 cysteine Nutrition 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 125000001072 heteroaryl group Chemical group 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 208000027866 inflammatory disease Diseases 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 206010061289 metastatic neoplasm Diseases 0.000 description 6
• 125000002950 monocyclic group Chemical group 0.000 description 6
• 230000001613 neoplastic effect Effects 0.000 description 6
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 6
• WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 5
• 208000023275 Autoimmune disease Diseases 0.000 description 5
• VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 5
• XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 5
• 229930195710 D‐cysteine Natural products 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 150000001336 alkenes Chemical group 0.000 description 5
• 210000000481 breast Anatomy 0.000 description 5
• 230000015556 catabolic process Effects 0.000 description 5
• 238000005119 centrifugation Methods 0.000 description 5
• 239000000460 chlorine Substances 0.000 description 5
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 238000006731 degradation reaction Methods 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 125000005843 halogen group Chemical group 0.000 description 5
• 230000003463 hyperproliferative effect Effects 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 208000032839 leukemia Diseases 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• LGAILEFNHXWAJP-BMEPFDOTSA-N macrocycle Chemical group N([C@H]1[C@@H](C)CC)C(=O)C(N=2)=CSC=2CNC(=O)C(=C(O2)C)N=C2[C@H]([C@@H](C)CC)NC(=O)C2=CSC1=N2 LGAILEFNHXWAJP-BMEPFDOTSA-N 0.000 description 5
• 239000012071 phase Substances 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• 230000002103 transcriptional effect Effects 0.000 description 5
• IJQLLGJUHGAQIC-LURJTMIESA-N (2s)-2-aminohept-6-ynoic acid Chemical compound OC(=O)[C@@H](N)CCCC#C IJQLLGJUHGAQIC-LURJTMIESA-N 0.000 description 4
• 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 4
• 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 4
• 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 4
• PKVWNYGXMNWJSI-CIUDSAMLSA-N Gln-Gln-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKVWNYGXMNWJSI-CIUDSAMLSA-N 0.000 description 4
• 208000012902 Nervous system disease Diseases 0.000 description 4
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 description 4
• 102000004142 Trypsin Human genes 0.000 description 4
• 108090000631 Trypsin Proteins 0.000 description 4
• 125000003545 alkoxy group Chemical group 0.000 description 4
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 150000001540 azides Chemical class 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 238000010511 deprotection reaction Methods 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 229910052731 fluorine Inorganic materials 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 238000007429 general method Methods 0.000 description 4
• 230000003394 haemopoietic effect Effects 0.000 description 4
• 201000009277 hairy cell leukemia Diseases 0.000 description 4
• 238000004128 high performance liquid chromatography Methods 0.000 description 4
• 206010020718 hyperplasia Diseases 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 229910052740 iodine Inorganic materials 0.000 description 4
• 238000005649 metathesis reaction Methods 0.000 description 4
• 239000000178 monomer Substances 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 229960003104 ornithine Drugs 0.000 description 4
• 230000002018 overexpression Effects 0.000 description 4
• 230000001575 pathological effect Effects 0.000 description 4
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 230000017854 proteolysis Effects 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 125000003396 thiol group Chemical group [H]S* 0.000 description 4
• 239000012588 trypsin Substances 0.000 description 4
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
• OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
• BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 3
• OFCPMJGTZUVUSM-UHFFFAOYSA-N 6-heptynoic acid Chemical compound OC(=O)CCCCC#C OFCPMJGTZUVUSM-UHFFFAOYSA-N 0.000 description 3
• 208000024827 Alzheimer disease Diseases 0.000 description 3
• 208000032467 Aplastic anaemia Diseases 0.000 description 3
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• CYTSBCIIEHUPDU-ACZMJKKPSA-N Gln-Asp-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O CYTSBCIIEHUPDU-ACZMJKKPSA-N 0.000 description 3
• 239000004201 L-cysteine Substances 0.000 description 3
• 235000013878 L-cysteine Nutrition 0.000 description 3
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• 208000025966 Neurological disease Diseases 0.000 description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 102000004079 Prolyl Hydroxylases Human genes 0.000 description 3
• 108010043005 Prolyl Hydroxylases Proteins 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
• 208000024780 Urticaria Diseases 0.000 description 3
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000035508 accumulation Effects 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 230000006978 adaptation Effects 0.000 description 3
• 150000001408 amides Chemical group 0.000 description 3
• 230000002424 anti-apoptotic effect Effects 0.000 description 3
• 229940041181 antineoplastic drug Drugs 0.000 description 3
• 239000003125 aqueous solvent Substances 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 230000033077 cellular process Effects 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 238000002983 circular dichroism Methods 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 230000010437 erythropoiesis Effects 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 3
• 125000000623 heterocyclic group Chemical group 0.000 description 3
• 230000033444 hydroxylation Effects 0.000 description 3
• 238000005805 hydroxylation reaction Methods 0.000 description 3
• 230000001146 hypoxic effect Effects 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 208000010125 myocardial infarction Diseases 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 230000002611 ovarian Effects 0.000 description 3
• 201000002528 pancreatic cancer Diseases 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 238000000159 protein binding assay Methods 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 238000010532 solid phase synthesis reaction Methods 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• 230000002194 synthesizing effect Effects 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 108091006108 transcriptional coactivators Proteins 0.000 description 3
• 150000003852 triazoles Chemical class 0.000 description 3
• 102100035070 von Hippel-Lindau disease tumor suppressor Human genes 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 229910052727 yttrium Inorganic materials 0.000 description 3
• CPUSCHYXEUZMSV-SSDOTTSWSA-N (2r)-2,6-diamino-2-methylhexanoic acid Chemical compound OC(=O)[C@@](N)(C)CCCCN CPUSCHYXEUZMSV-SSDOTTSWSA-N 0.000 description 2
• XDTDZXZZJXVVOL-MRVPVSSYSA-N (2r)-2-amino-2-methylhept-6-ynoic acid Chemical compound OC(=O)[C@@](N)(C)CCCC#C XDTDZXZZJXVVOL-MRVPVSSYSA-N 0.000 description 2
• JMHBRCHHTBVRNO-SSDOTTSWSA-N (2r)-2-amino-2-methylhex-5-ynoic acid Chemical compound OC(=O)[C@@](N)(C)CCC#C JMHBRCHHTBVRNO-SSDOTTSWSA-N 0.000 description 2
• OCVMRPUTOUMOLZ-SNVBAGLBSA-N (2r)-2-amino-2-methylnon-8-ynoic acid Chemical compound OC(=O)[C@@](N)(C)CCCCCC#C OCVMRPUTOUMOLZ-SNVBAGLBSA-N 0.000 description 2
• WTFKXZRWELKUFM-SECBINFHSA-N (2r)-2-amino-2-methyloct-7-ynoic acid Chemical compound OC(=O)[C@@](N)(C)CCCCC#C WTFKXZRWELKUFM-SECBINFHSA-N 0.000 description 2
• FSBNDYYRTZBHAN-ZCFIWIBFSA-N (2r)-2-amino-2-methylpent-4-ynoic acid Chemical compound OC(=O)[C@@](N)(C)CC#C FSBNDYYRTZBHAN-ZCFIWIBFSA-N 0.000 description 2
• DGYHPLMPMRKMPD-SCSAIBSYSA-N (2r)-2-azaniumylpent-4-ynoate Chemical compound OC(=O)[C@H](N)CC#C DGYHPLMPMRKMPD-SCSAIBSYSA-N 0.000 description 2
• CPUSCHYXEUZMSV-ZETCQYMHSA-N (2s)-2,6-diamino-2-methylhexanoic acid Chemical compound OC(=O)[C@](N)(C)CCCCN CPUSCHYXEUZMSV-ZETCQYMHSA-N 0.000 description 2
• JMHBRCHHTBVRNO-ZETCQYMHSA-N (2s)-2-amino-2-methylhex-5-ynoic acid Chemical compound OC(=O)[C@](N)(C)CCC#C JMHBRCHHTBVRNO-ZETCQYMHSA-N 0.000 description 2
• OCVMRPUTOUMOLZ-JTQLQIEISA-N (2s)-2-amino-2-methylnon-8-ynoic acid Chemical compound OC(=O)[C@](N)(C)CCCCCC#C OCVMRPUTOUMOLZ-JTQLQIEISA-N 0.000 description 2
• WTFKXZRWELKUFM-VIFPVBQESA-N (2s)-2-amino-2-methyloct-7-ynoic acid Chemical compound OC(=O)[C@](N)(C)CCCCC#C WTFKXZRWELKUFM-VIFPVBQESA-N 0.000 description 2
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 208000003200 Adenoma Diseases 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• 208000037259 Amyloid Plaque Diseases 0.000 description 2
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000005623 Carcinogenesis Diseases 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 208000006332 Choriocarcinoma Diseases 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 201000008808 Fibrosarcoma Diseases 0.000 description 2
• 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 2
• 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 2
• 208000007465 Giant cell arteritis Diseases 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 108090000246 Histone acetyltransferases Proteins 0.000 description 2
• 102000003893 Histone acetyltransferases Human genes 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 208000007054 Medullary Carcinoma Diseases 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• 238000011789 NOD SCID mouse Methods 0.000 description 2
• 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 208000002151 Pleural effusion Diseases 0.000 description 2
• 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 108700005078 Synthetic Genes Proteins 0.000 description 2
• 206010043276 Teratoma Diseases 0.000 description 2
• 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
• 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 238000005865 alkene metathesis reaction Methods 0.000 description 2
• 125000005157 alkyl carboxy group Chemical group 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 239000012148 binding buffer Substances 0.000 description 2
• 238000005415 bioluminescence Methods 0.000 description 2
• 230000029918 bioluminescence Effects 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 231100000504 carcinogenesis Toxicity 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000003833 cell viability Effects 0.000 description 2
• 230000004700 cellular uptake Effects 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 230000009137 competitive binding Effects 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 210000001671 embryonic stem cell Anatomy 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 206010017758 gastric cancer Diseases 0.000 description 2
• 230000004153 glucose metabolism Effects 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 2
• 201000010536 head and neck cancer Diseases 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 208000014951 hematologic disease Diseases 0.000 description 2
• 125000004475 heteroaralkyl group Chemical group 0.000 description 2
• 125000005114 heteroarylalkoxy group Chemical group 0.000 description 2
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
• 239000000833 heterodimer Substances 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
• 230000002390 hyperplastic effect Effects 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 201000003159 intraductal papilloma Diseases 0.000 description 2
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
• 238000004020 luminiscence type Methods 0.000 description 2
• 210000004324 lymphatic system Anatomy 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 238000011580 nude mouse model Methods 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 201000010198 papillary carcinoma Diseases 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000000902 placebo Substances 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 238000006116 polymerization reaction Methods 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 239000000700 radioactive tracer Substances 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 238000000611 regression analysis Methods 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 206010043207 temporal arteritis Diseases 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 150000003568 thioethers Chemical class 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000000844 transformation Methods 0.000 description 2
• 229910052723 transition metal Inorganic materials 0.000 description 2
• 150000003624 transition metals Chemical class 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 230000005751 tumor progression Effects 0.000 description 2
• 229910052721 tungsten Inorganic materials 0.000 description 2
• 229910052720 vanadium Inorganic materials 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• DMGYERSWNFEQDT-RXMQYKEDSA-N (2R)-2-(methylamino)pent-4-ynoic acid Chemical compound CN[C@H](CC#C)C(=O)O DMGYERSWNFEQDT-RXMQYKEDSA-N 0.000 description 1
• OZRWQPFBXDVLAH-RXMQYKEDSA-N (2r)-5-amino-2-(methylamino)pentanoic acid Chemical compound CN[C@@H](C(O)=O)CCCN OZRWQPFBXDVLAH-RXMQYKEDSA-N 0.000 description 1
• WLNBMPZUVDTASE-HXIISURNSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO WLNBMPZUVDTASE-HXIISURNSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• GDQWQDLPDMZFIE-OAQYLSRUSA-N (2s)-2-[methoxy(trityl)amino]-3-sulfanylpropanoic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N([C@H](CS)C(O)=O)OC)C1=CC=CC=C1 GDQWQDLPDMZFIE-OAQYLSRUSA-N 0.000 description 1
• FZVNGRBNGFKOSD-UHFFFAOYSA-N 1,2-difluorodecane Chemical compound CCCCCCCCC(F)CF FZVNGRBNGFKOSD-UHFFFAOYSA-N 0.000 description 1
• OHZUYIYVVGVSCE-UHFFFAOYSA-N 1,3-dimethylcyclodecane Chemical compound CC1CCCCCCCC(C)C1 OHZUYIYVVGVSCE-UHFFFAOYSA-N 0.000 description 1
• RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• KXSKAZFMTGADIV-UHFFFAOYSA-N 2-[3-(2-hydroxyethoxy)propoxy]ethanol Chemical group OCCOCCCOCCO KXSKAZFMTGADIV-UHFFFAOYSA-N 0.000 description 1
• PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
• WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
• XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
• FODXEDDYIKFWFZ-UHFFFAOYSA-N 2-methylnon-8-ynoic acid Chemical compound OC(=O)C(C)CCCCCC#C FODXEDDYIKFWFZ-UHFFFAOYSA-N 0.000 description 1
• CIEGZJJPCMMEKE-UHFFFAOYSA-N 2-methyloct-7-ynoic acid Chemical compound OC(=O)C(C)CCCCC#C CIEGZJJPCMMEKE-UHFFFAOYSA-N 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• 102100025425 2-oxoglutarate and iron-dependent oxygenase JMJD4 Human genes 0.000 description 1
• UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 208000023769 AA amyloidosis Diseases 0.000 description 1
• 208000018282 ACys amyloidosis Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 101710131701 Adenylate kinase 3 Proteins 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• 206010049153 Allergic sinusitis Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 102100038910 Alpha-enolase Human genes 0.000 description 1
• 101710165425 Alpha-enolase Proteins 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 101800001718 Amyloid-beta protein Proteins 0.000 description 1
• 206010002025 Amyloidosis senile Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 208000028185 Angioedema Diseases 0.000 description 1
• 201000003076 Angiosarcoma Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 108090000672 Annexin A5 Proteins 0.000 description 1
• 102000004121 Annexin A5 Human genes 0.000 description 1
• 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 208000007690 Brenner tumor Diseases 0.000 description 1
• 206010073258 Brenner tumour Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
• 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• VKBAXDOFWIBJNN-UHFFFAOYSA-N CC(C(=O)O)CCCC#C.CC(C(=O)O)CCCC#C Chemical compound CC(C(=O)O)CCCC#C.CC(C(=O)O)CCCC#C VKBAXDOFWIBJNN-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 206010007509 Cardiac amyloidosis Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
• 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
• 108010075016 Ceruloplasmin Proteins 0.000 description 1
• 102100023321 Ceruloplasmin Human genes 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 208000024699 Chagas disease Diseases 0.000 description 1
• 241000252505 Characidae Species 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 206010010099 Combined immunodeficiency Diseases 0.000 description 1
• 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
• 208000025212 Constitutional neutropenia Diseases 0.000 description 1
• 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
• 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 229910017489 Cu I Inorganic materials 0.000 description 1
• JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical class [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FFFHZYDWPBMWHY-GSVOUGTGSA-N D-Homocysteine Chemical compound OC(=O)[C@H](N)CCS FFFHZYDWPBMWHY-GSVOUGTGSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
• 101100278318 Dictyostelium discoideum dohh-2 gene Proteins 0.000 description 1
• 201000010374 Down Syndrome Diseases 0.000 description 1
• 206010013700 Drug hypersensitivity Diseases 0.000 description 1
• 208000007033 Dysgerminoma Diseases 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 102400000686 Endothelin-1 Human genes 0.000 description 1
• 101800004490 Endothelin-1 Proteins 0.000 description 1
• 101710184673 Enolase 1 Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 1
• 206010016202 Familial Amyloidosis Diseases 0.000 description 1
• 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 1
• 201000004939 Fanconi anemia Diseases 0.000 description 1
• 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
• 208000007659 Fibroadenoma Diseases 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 206010070531 Foetal growth restriction Diseases 0.000 description 1
• 208000004262 Food Hypersensitivity Diseases 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 101710191368 GTP:AMP phosphotransferase AK3, mitochondrial Proteins 0.000 description 1
• 102100033512 GTP:AMP phosphotransferase AK3, mitochondrial Human genes 0.000 description 1
• 101710184523 GTP:AMP phosphotransferase, mitochondrial Proteins 0.000 description 1
• 240000005702 Galium aparine Species 0.000 description 1
• 235000014820 Galium aparine Nutrition 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
• 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 108091052347 Glucose transporter family Proteins 0.000 description 1
• 102000042092 Glucose transporter family Human genes 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 208000001204 Hashimoto Disease Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
• 108010018924 Heme Oxygenase-1 Proteins 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 208000032838 Hereditary amyloidosis with primary renal involvement Diseases 0.000 description 1
• 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 1
• 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000934666 Homo sapiens 2-oxoglutarate and iron-dependent oxygenase JMJD4 Proteins 0.000 description 1
• 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
• 101000604197 Homo sapiens Neuronatin Proteins 0.000 description 1
• 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
• 101000693243 Homo sapiens Paternally-expressed gene 3 protein Chemical group 0.000 description 1
• 101000587313 Homo sapiens Tyrosine-protein kinase Srms Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 208000031226 Hyperlipidaemia Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010052210 Infantile genetic agranulocytosis Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
• 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
• 208000005615 Interstitial Cystitis Diseases 0.000 description 1
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
• 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
• 208000000209 Isaacs syndrome Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 208000000675 Krukenberg Tumor Diseases 0.000 description 1
• FFFHZYDWPBMWHY-UHFFFAOYSA-N L-Homocysteine Natural products OC(=O)C(N)CCS FFFHZYDWPBMWHY-UHFFFAOYSA-N 0.000 description 1
• 235000019766 L-Lysine Nutrition 0.000 description 1
• QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
• FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
• 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
• 208000000185 Localized scleroderma Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 206010027462 Metastases to ovary Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 206010027982 Morphoea Diseases 0.000 description 1
• 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
• 208000005927 Myosarcoma Diseases 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 238000011887 Necropsy Methods 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 206010072359 Neuromyotonia Diseases 0.000 description 1
• 102100038816 Neuronatin Human genes 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
• 241001666145 Noia Species 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 1
• 102100037223 Nuclear receptor coactivator 1 Human genes 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 101100338491 Oryza sativa subsp. japonica HCT1 gene Proteins 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 102100025757 Paternally-expressed gene 3 protein Human genes 0.000 description 1
• 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 201000011152 Pemphigus Diseases 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
• 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 1
• 208000002163 Phyllodes Tumor Diseases 0.000 description 1
• 206010071776 Phyllodes tumour Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
• 206010035610 Pleural Neoplasms Diseases 0.000 description 1
• 208000002664 Pleural Solitary Fibrous Tumor Diseases 0.000 description 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
• 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 102000013009 Pyruvate Kinase Human genes 0.000 description 1
• 108020005115 Pyruvate Kinase Proteins 0.000 description 1
• 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
• 108091006296 SLC2A1 Proteins 0.000 description 1
• 101100495309 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDH1 gene Proteins 0.000 description 1
• 239000002262 Schiff base Substances 0.000 description 1
• 150000004753 Schiff bases Chemical class 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 208000006045 Spondylarthropathies Diseases 0.000 description 1
• 208000035518 Squamous cell carcinoma of the oropharynx Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 201000000331 Testicular germ cell cancer Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 206010044688 Trisomy 21 Diseases 0.000 description 1
• 241000209140 Triticum Species 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 102100029654 Tyrosine-protein kinase Srms Human genes 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 206010048215 Xanthomatosis Diseases 0.000 description 1
• 241000021375 Xenogenes Species 0.000 description 1
• 208000012018 Yolk sac tumor Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000004064 acoustic neuroma Diseases 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 230000009056 active transport Effects 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
• 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
• 230000008649 adaptation response Effects 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 108010063640 adrenomedullin receptors Proteins 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
• 125000002877 alkyl aryl group Chemical group 0.000 description 1
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 206010002022 amyloidosis Diseases 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 230000003443 anti-oncogenic effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 206010002906 aortic stenosis Diseases 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 208000004670 arteriolosclerosis Diseases 0.000 description 1
• 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
• 150000001502 aryl halides Chemical class 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000001746 atrial effect Effects 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 208000027625 autoimmune inner ear disease Diseases 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
• 239000012965 benzophenone Substances 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• PNPBGYBHLCEVMK-UHFFFAOYSA-N benzylidene(dichloro)ruthenium;tricyclohexylphosphanium Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-N 0.000 description 1
• 201000007180 bile duct carcinoma Diseases 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
• 201000001531 bladder carcinoma Diseases 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 201000005389 breast carcinoma in situ Diseases 0.000 description 1
• 201000003149 breast fibroadenoma Diseases 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 208000025434 cerebellar degeneration Diseases 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• ZRZWBWPDBOVIGQ-OKMJTBRXSA-N chaetomin Chemical compound C1=C(C[C@]23C(N(C)[C@@](CO)(SS2)C(=O)N3C)=O)C2=CC=CC=C2N1[C@@]12C[C@]3(SS4)C(=O)N(C)[C@]4(CO)C(=O)N3[C@H]2NC2=CC=CC=C12 ZRZWBWPDBOVIGQ-OKMJTBRXSA-N 0.000 description 1
• DZRJLJPPUJADOO-UHFFFAOYSA-N chaetomin Natural products CN1C(=O)C2(Cc3cn(C)c4ccccc34)SSC1(CO)C(=O)N2C56CC78SSC(CO)(N(C)C7=O)C(=O)N8C5Nc9ccccc69 DZRJLJPPUJADOO-UHFFFAOYSA-N 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• AHWRJPOOFGXEKF-UHFFFAOYSA-M chlororuthenium(1+);1,2,3,4,5-pentamethylcyclopenta-1,3-diene;triphenylphosphane Chemical compound [Ru+]Cl.CC=1C(C)=C(C)[C-](C)C=1C.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 AHWRJPOOFGXEKF-UHFFFAOYSA-M 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 238000001142 circular dichroism spectrum Methods 0.000 description 1
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 230000004732 colorectal carcinogenesis Effects 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 208000016576 colorectal neuroendocrine tumor G1 Diseases 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 208000035195 congenital hypomyelinating 3 neuropathy Diseases 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• LMGZGXSXHCMSAA-UHFFFAOYSA-N cyclodecane Chemical compound C1CCCCCCCCC1 LMGZGXSXHCMSAA-UHFFFAOYSA-N 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 208000007321 cystadenofibroma Diseases 0.000 description 1
• 150000001945 cysteines Chemical class 0.000 description 1
• 231100000895 deafness Toxicity 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 201000011190 diabetic macular edema Diseases 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
• 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 208000001991 endodermal sinus tumor Diseases 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 208000027858 endometrioid tumor Diseases 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 230000000925 erythroid effect Effects 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 201000007891 familial visceral amyloidosis Diseases 0.000 description 1
• 201000010972 female reproductive endometrioid cancer Diseases 0.000 description 1
• 208000030941 fetal growth restriction Diseases 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• PTCGDEVVHUXTMP-UHFFFAOYSA-N flutolanil Chemical compound CC(C)OC1=CC=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 PTCGDEVVHUXTMP-UHFFFAOYSA-N 0.000 description 1
• 230000004907 flux Effects 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 235000020932 food allergy Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 208000010749 gastric carcinoma Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000002518 glial effect Effects 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 230000004190 glucose uptake Effects 0.000 description 1
• 125000003827 glycol group Chemical group 0.000 description 1
• 208000003064 gonadoblastoma Diseases 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000011984 grubbs catalyst Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 201000000079 gynecomastia Diseases 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 208000002557 hidradenitis Diseases 0.000 description 1
• 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 230000003118 histopathologic effect Effects 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 208000015210 hypertensive heart disease Diseases 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 230000001096 hypoplastic effect Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000011503 in vivo imaging Methods 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 238000013152 interventional procedure Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 235000005772 leucine Nutrition 0.000 description 1
• 125000001909 leucine group Chemical class [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 201000011059 lobular neoplasia Diseases 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 208000008585 mastocytosis Diseases 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
• 229910052753 mercury Inorganic materials 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 201000002335 monodermal teratoma Diseases 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 208000022669 mucinous neoplasm Diseases 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 108091005763 multidomain proteins Proteins 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 201000002077 muscle cancer Diseases 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 201000003631 narcolepsy Diseases 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 208000012108 neoplastic polyp Diseases 0.000 description 1
• 201000011519 neuroendocrine tumor Diseases 0.000 description 1
• 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
• 230000007514 neuronal growth Effects 0.000 description 1
• 208000004235 neutropenia Diseases 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 231100001221 nontumorigenic Toxicity 0.000 description 1
• 230000007959 normoxia Effects 0.000 description 1
• 150000007523 nucleic acids Chemical group 0.000 description 1
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 229910052762 osmium Inorganic materials 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 208000025207 ovarian monodermal teratoma Diseases 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 125000004043 oxo group Chemical group O=* 0.000 description 1
• 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
• 208000021255 pancreatic insulinoma Diseases 0.000 description 1
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 230000009038 pharmacological inhibition Effects 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 210000004224 pleura Anatomy 0.000 description 1
• 201000003437 pleural cancer Diseases 0.000 description 1
• 201000003144 pneumothorax Diseases 0.000 description 1
• 229920001515 polyalkylene glycol Polymers 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 229920005990 polystyrene resin Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 150000003141 primary amines Chemical group 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 208000035803 proliferative type breast fibrocystic change Diseases 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 230000004063 proteosomal degradation Effects 0.000 description 1
• 208000007153 proteostasis deficiencies Diseases 0.000 description 1
• 239000003586 protic polar solvent Substances 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 238000011127 radiochemotherapy Methods 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 208000032253 retinal ischemia Diseases 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 238000006798 ring closing metathesis reaction Methods 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 229910052707 ruthenium Inorganic materials 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 201000008662 sclerosing adenosis of breast Diseases 0.000 description 1
• 208000008864 scrapie Diseases 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 239000004017 serum-free culture medium Substances 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000010378 sodium ascorbate Nutrition 0.000 description 1
• PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
• 229960005055 sodium ascorbate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 208000014653 solitary fibrous tumor Diseases 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 201000005671 spondyloarthropathy Diseases 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 230000002739 subcortical effect Effects 0.000 description 1
• WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 102000013498 tau Proteins Human genes 0.000 description 1
• 108010026424 tau Proteins Proteins 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 208000001644 thecoma Diseases 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000005309 thioalkoxy group Chemical group 0.000 description 1
• 150000003573 thiols Chemical group 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 108091006106 transcriptional activators Proteins 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 201000007905 transthyretin amyloidosis Diseases 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 201000007423 tubular adenocarcinoma Diseases 0.000 description 1
• 230000005740 tumor formation Effects 0.000 description 1
• 231100000588 tumorigenic Toxicity 0.000 description 1
• 230000000381 tumorigenic effect Effects 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 230000009452 underexpressoin Effects 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000037314 wound repair Effects 0.000 description 1